Loading
Nuvasive Inc Stock: price and insider trades · United States
Nuvasive Inc: what insiders have been doing
Nuvasive Inc, classified in the Healthcare & Pharma sector, is a listed company based in San Diego, United States, founded in 1997. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Nuvasive Inc in twelve months, the latest record being from 5 September 2023.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
71
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€1M
17 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$1B
Gross profitUS$745.1M72% margin
Net incomeUS$34.8M3.4% margin
Last declaration on 5 September 2023
Declarations71 total
8,943 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048175:0
3,095 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048186:0
22,423 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048173:0
3,739 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048185:0
72,997 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048164:0
3,117 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048168:0
1,360 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048184:0
11,081 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048171:0
2,000 sharesCommon Stock, par value $0.001 per shareSEC:0001209191-23-048177:0
4,572 shares0Common StockSEC:0001209191-23-015858:0
1,905 shares0Common StockSEC:0001209191-23-015854:0
34,284 shares0Common StockSEC:0001209191-23-015840:0
12,190 shares0Common StockSEC:0001209191-23-015847:0
1,829 shares0Common StockSEC:0001209191-23-015860:0
5,333 shares0Common StockSEC:0001209191-23-015851:0
1,286 shares0Common StockSEC:0001209191-23-000364:0
3,739 shares0Common StockSEC:0001209191-22-033194:0
1,547 shares0Common StockSEC:0001209191-22-033199:0
13,326 shares0Common StockSEC:0001209191-22-028954:0
5,000 shares@ US$58.0024.3% of flowCommon StockSEC:0001209191-22-024530:0
5,000 shares@ US$55.0022.8% of flowCommon StockSEC:0001209191-22-021639:0
8,699 shares0Common StockSEC:0001209191-22-015757:0
4,015 shares0Common StockSEC:0001209191-22-015775:0
8,029 shares0Common StockSEC:0001209191-22-015766:0
53,523 shares0Common StockSEC:0001209191-22-015756:0
25 of 71 declarations
About Nuvasive Inc
NuVasive, Inc. was a U.S.-based medical device company focused on spine surgery and spinal care technologies. It was historically listed on the NASDAQ in the United States under the ticker NUVA. Founded in 1997, the company built its identity around minimally invasive spine surgery and procedurally integrated solutions designed to improve surgical precision, reduce tissue disruption, and support better clinical workflows. Its headquarters were in San Diego, California, and it maintained an international commercial footprint beyond the United States.
NuVasive’s business model centered on spine implants, surgical instruments, biologics-related offerings, and enabling technologies used in complex spinal procedures. In addition to hardware, the company emphasized surgeon education, training programs, and clinical support services. That mix of products and services helped differentiate NuVasive in a highly competitive orthopedic and spine market where adoption depends on surgeon preference, clinical evidence, hospital economics, and technology integration. Its main competitive set included large medtech names active in spine such as Globus Medical, Medtronic, and Stryker.
Read moreShow less
From a historical perspective, NuVasive emerged as a specialist in less-invasive spine surgery and gradually broadened its portfolio to address a wider range of spinal pathologies and procedure types. The company’s strategy was to combine innovation with a strong procedural ecosystem, aiming to become a leading spine technology platform. It also developed a broader geographic presence, serving the U.S. market while expanding internationally through distributor relationships and surgeon-engagement programs, including activity in Asia-Pacific.
The key recent development is corporate integration rather than standalone operating growth. In February 2023, NuVasive agreed to combine with Globus Medical in an all-stock merger. The transaction closed on September 1, 2023, and NuVasive common stock ceased trading on the NASDAQ at the close of trading on August 31, 2023. As a result, NuVasive no longer exists as an independent listed equity; it became a wholly owned subsidiary of Globus Medical. For investors, that means NUVA is now primarily relevant for historical analysis, legacy filings, and understanding the evolution of the U.S. spine device industry.
For SEO and market-context purposes, NuVasive should therefore be described as a former NASDAQ-listed U.S. medtech company in the Health & Pharma sector, with a legacy franchise in spine surgery, minimally invasive procedures, surgeon education, and international commercialization, now absorbed into Globus Medical.
